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Abstract

Background: Development of vaccines against human immunodeficiency virus (HIV)
infection is a worldwide public-health priority. We evaluated the population effects of potential preventive and therapeutic vaccines in early-and late-stage epidemics in a population of homosexual men.
Methods:
We used an epidemic model that simulated the course of the epidemic for a population designed to reflect that of homosexual men in San Francisco, California. We evaluated vaccine programs by the number of cases of HIV averted, the effect on the prevalence of HIV, and by the gain in quality-adjusted life years (QALYs) for the total population. (preventive or therapeutic) is important, because it determines who is vaccinated and bears any risk associated with vaccination, who benefits from a vaccine program (the uninfected or the infected population), how many people are vaccinated (usually, the infected population is smaller than the uninfected population), and, perhaps, how the course of the epidemic unfolds.
We report our use of a mathematical model to evaluate the population effects of potential preventive and therapeutic vaccines in early-and late-stage epidemics in a population of homosexual men. We sought to determine the effect of therapeutic or preventive HIV vaccine programs on the number of HIV infections averted, the prevalence of HIV, and the total number of quality-adjusted life years accrued by the population. We performed our analyses by simulating the course of the HIV epidemic under various vaccine programs, in a population matched to resemble a population of homosexual men.
Methods
Model Structure. We used a dynamic, compartmental epidemic model 13-16 that simulated the course of the epidemic for a population designed to reflect that of homosexual men in San Francisco, California (Figure 1 ). Compartmental models are a standard approach for modeling the course of an epidemic caused by an infectious disease. Mathematical equations govern the rate at which people move over time from one compartment (a population subgroup, represented by a box in Figure 1 A detailed description of the model, assumptions, and sources of data is available. 17
The model incorporated the vaccine characteristics of take, efficacy, duration, and effect on infectivity. 15,16 For a preventive vaccine, the take of the vaccine, ψ, is the percentage of people in whom the vaccine has any effect. The efficacy of the vaccine, ε, is the proportion of people protected from infection, among those people in whom the vaccine takes. The duration of the vaccine, 1/ω, is the length of time (in years) that the vaccine provides protection. For a therapeutic vaccine, take is defined similarly. For simplicity, we assumed that the effects of therapeutic vaccines on length of life and infectivity were confined to the asymptomatic period of HIV disease. The decrease in the rate of progression to symptomatic disease caused by a preventive vaccine results in additional longevity in the asymptomatic period; this additional longevity is 1/µ ν (in years). We defined infectivity as the probability of transmission of HIV per partnership. The infectivity during the asymptomatic period, β α , is reduced by a factor, β ν , the infectivity reduction of a therapeutic vaccine. Thus, the infectivity of a person who received the therapeutic vaccine was equal to (β α )(β ν ).
To illustrate how we developed the equations that govern transition among the population subgroups, we explain the equation for the number of people in the uninfected, unvaccinated subpopulation ( Figure 1, box and the probability, per partnership, of acquiring HIV, λ(t), or X(t)cλ(t). The number of people who left the uninfected population due to death from other causes (not shown in Figure   1 ) was the product of the number of uninfected unvaccinated people, X(t), and the non-AIDS death rate, µ, or X(t)µ. Finally, the number of people who reentered the susceptible population because their vaccine protection had waned was the product of the number of vaccinated people, X ν (t), and the rate of loss of vaccine protection, ω, or X ν (t)ω.
Thus, the number of unvaccinated susceptible people varied according to
Transitions between other compartments in Figure 1 were governed by similar equations. 17
We modeled the effect of a preventive vaccine program as a change in the rate of HIV infection in susceptible individuals exposed to HIV. In the unvaccinated group, the number of 6 
new HIV infections in susceptible individuals was X(t)cλ(t). In the vaccinated susceptible group, the number of new infections was X(t)cλ(t)(1 -ε).
Thus, the rate of infection of susceptible people was reduced by the term (1 -ε). For example, if the preventive vaccine efficacy was 70% (ε = 0.7), the rate of new infections was reduced to 30% of the unvaccinated rate.
We modeled the effect of a therapeutic vaccine as a decreased rate of transition from the asymptomatic to the symptomatic state. We assumed that therapeutic-vaccine efficacy was independent of antiretroviral treatment, and, for our base-case analysis, that vaccine programs did not alter sexual risk behaviors. In subsequent analyses, we examined changes in risk behavior. We also assumed that the uninfected population and the infected asymptomatic, Because the vaccine characteristics for preventive and therapeutic vaccines are unknown, we evaluated the possible future effects of vaccine programs under a wide range of assumptions about vaccine characteristics (Table 1 ). For our base-case analysis, we evaluated a preventive vaccine that produced a response in all vaccinated individuals (take = 1), protected 75% of these individuals from infection (efficacy = 75%), and provided protection for 10 years an unusually large number of HIV cases was seen. We performed sensitivity analyses on all model variables.
Results
Our analysis was performed for a population of 55,800 homosexual men. Our base-case analyses assumed that a therapeutic vaccine did not reduce the infectivity of vaccinated people. However, the population effects of a therapeutic vaccine depend on the balance between the degree to which a vaccine recipient's longevity is increased (and thus transmission of HIV is increased) and the degree to which the recipient's infectivity is reduced.
Effect of Vaccine
For example, a therapeutic vaccine that increased length of life by 5 years, but reduced infectivity by 50%, could produce net gains in quality-adjusted life years similar to those produced by a preventive vaccine with a duration of 10 years and an efficacy of 62.4% ( Figure   4 ). In contrast to our base-case analysis, a therapeutic vaccine that reduced infectivity by (Figures 3b and 3d) .
Discussion
We used an epidemic model to estimate the effects of programs with preventive or therapeutic HIV vaccines on a population of homosexual men. Our analysis has three main findings. First, although both preventive-and therapeutic-vaccine programs provided substantial benefit, their relative merit depended on which outcome measures we assessed.
Preventive Our third finding is that the relative merits of preventive and therapeutic vaccines also depended on the stage of the epidemic. The relative advantage of preventive vaccines was most pronounced in early-stage epidemics, a finding that held for a variety of vaccine characteristics.
In an early-stage epidemic, the number of uninfected persons in whom vaccination can prevent infection is greater than in a late-stage epidemic, or in an epidemic that is growing slowly.
Thus, a preventive vaccine holds more promise in an early-stage epidemic compared with a therapeutic vaccine that reduces infectivity modestly, or not at all. Our analysis also has implications for the design of clinical trials of HIV vaccines.
Differences in vaccine take, efficacy, and duration result in predictable patterns of HIV incidence in the study population. 15,16 Our results suggest that field vaccine trials also should evaluate correlates of infectivity, such as HIV viral load. These estimates will help investigators to determine whether therapeutic and preventive vaccines produce similar, or markedly distinct, effects on the course of the HIV epidemic. Transition from population subgroups b and d to groups a and c occurred when members of the population were vaccinated with a preventive vaccine; transition in the opposite direction occurred when vaccine protection waned. Transition from d to e occurred when a person who was infected but unaware of his infection was identified through screening. We assumed that 15% of the asymptomatic, HIV-infected population was screened and identified annually.
Transition from e or f to g occurred from disease progression. Transition from e to f occurred when an asymptomatic HIV-infected person received a therapeutic vaccine. 
